Is Citizens, Inc. (Austin, Texas) overvalued or undervalued?

As of 10 October 2025, the valuation grade for Citizens, Inc. has moved from expensive to very expensive, indicating a significant deterioration in its valuation appeal. The company is overvalued, with a P/E ratio of 23, which is notably higher than its peer Abacus Life, Inc. at 25.63 and significantly higher than eHealth, Inc. at just 4.03. Additionally, the EV to EBITDA ratio stands at an alarming 129.70, further emphasizing the overvaluation, especially when compared to eHealth's much lower ratio of 0.90.
In terms of recent performance, Citizens, Inc. has shown a year-to-date return of 32.67%, outperforming the S&P 500's return of 11.41% during the same period. However, over the longer term, the company's 5-year return of -9.22% starkly contrasts with the S&P 500's 88.45%, highlighting concerns about its sustainability and growth potential. Overall, the combination of high valuation ratios and inconsistent performance suggests that Citizens, Inc. is not a compelling investment at its current price.